Related Experiment Videos
DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats
Heidi C O'Neill1, Kate Rieger, William R Kem
1Department of Psychiatry C268-71, University of Colorado Health Sciences Center, 4200 East 9th Avenue,Denver, CO 80262, USA.
Psychopharmacology
|May 22, 2003
Summary
The alpha(7) nicotinic agonist DMXB (GTS-21) improved auditory gating deficits in isolation-reared rats, mimicking schizophrenia symptoms. However, high doses impaired gating in control rats, suggesting dose-dependent effects.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Impaired auditory gating is a common deficit in schizophrenia patients.
- This deficit is linked to reduced alpha(7) nicotinic receptors.
- Alpha(7) nicotinic agonists, like DMXB (GTS-21), may offer therapeutic benefits.
Purpose of the Study:
- To investigate the effects of DMXB on auditory gating in rats.
- To compare DMXB's impact on isolation-reared rats (exhibiting gating deficits) and control rats.
Main Methods:
- Surgically implanted electrodes for baseline recordings in rats.
- Administration of varying doses of DMXB (1.0-33 mg/kg, IP) to assess auditory gating.
- Comparison between isolation-reared and control rat groups.
Main Results:
- DMXB significantly improved auditory gating in isolation-reared rats at doses of 3.33, 10, and 33 mg/kg.
- Control rats showed impaired auditory gating at the highest dose (33 mg/kg).
- Improvements in isolation-reared rats were associated with decreased test amplitude.
Conclusions:
- DMXB effectively ameliorated auditory gating deficits in isolation-reared rats.
- The findings support DMXB's potential as a therapeutic agent for conditions with auditory gating impairments.
- Dose-dependent effects of DMXB on auditory gating were observed in both experimental groups.